PTK/ZK (Vatalanib) for advanced metastatic colorectal cancer - horizon scanning review
National Horizon Scanning Centre
Record ID 32005000232
English
Authors' objectives:
This study aims to assess the effectiveness of PTK/ZK (Vatalanib) for advanced metastatic colorectal cancer.
Authors' recommendations:
PTK/ZK is an oral angiogenesis inhibitor that selectively inhibits the tyrosine kinase domains of vascular endothelial growth factor (VEGF) receptors, platelet-derived growth factor (PDGF) receptor, and c-KIT. PTK/ZK in combination with oxaliplatin and 5-FU and leucovorin has completed phase III trials as 1st line therapy and 2nd line therapy, (after irinotecan-based chemotherapy), in advanced metastatic colorectal cancer. Results should be available during 2005.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
http://www.pcpoh.bham.ac.uk/publichealth/horizon/
Year Published:
2005
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antineoplastic Agents
- Neoplasm Metastasis
- Colorectal Neoplasms
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.